Melanóma: vizsgálatok itt: Görögország
7 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleStudy to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
- Where
- Efkarpia
- Életkor
- 18 év and over
- People
- 632 worldwide
- Run by
- mAbxience Research S.L.
See details and how to joinNCT07221734 - 1. fázisTaking peopleA PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III melanoma in the adjuvant setting
- Where
- Thessaloniki
- Életkor
- 18 év and over
- People
- 83 worldwide
- Run by
- H e x a l AG
See details and how to join2025-521919-39-00 · EU 2025-521919-39-00 - 3. fázisTaking peopleStudy to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Where
- Athens, Patras
- Életkor
- 18 év to 70 év
- People
- 670 worldwide
- Run by
- Iovance Biotherapeutics, Inc.
See details and how to joinNCT05727904 · EU 2022-503140-41-00 - 3. fázisTaking peopleVO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
- Where
- Athens, Efkarpia
- Életkor
- 12 év and over
- People
- 400 worldwide
- Run by
- Replimune, Inc.
See details and how to joinNCT06264180 · EU 2023-508612-29-00 - 3. fázisTaking peopleRandomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
- Where
- Cholargos, Efkarpia
- Életkor
- 18 év and over
- People
- 119 worldwide
- Run by
- Mabxience Research S.L.
See details and how to join2025-521562-95-00 · EU 2025-521562-95-00 - 3. fázisTaking peopleNeoadjuvant Darovasertib in Primary Uveal Melanoma
- Where
- Heraklion, Larissa, Thessaloniki
- Életkor
- 18 év and over
- People
- 520 worldwide
- Run by
- IDEAYA Biosciences
See details and how to joinNCT07015190 · EU 2025-522387-32-00 - 4. fázisTaking peopleA Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
- Where
- Athens
- Életkor
- 18 év and over
- People
- 50 worldwide
- Run by
- Replimune, Inc.
See details and how to joinNCT06887348 · EU 2025-521621-33-00